Ashfield launches cell and gene therapy commercialization network
Ashfield, part of UDG Healthcare plc, has launched EmerGENE, a global end-to-end cell and gene therapy network approach that management says promises to support small and midsize biotechs with the commercialization of their discoveries.
“The first of its kind in the industry, EmerGENE has been built by a multidisciplinary team that delivers expert-led guidance and services to biotechs throughout their entire clinical to commercial journey,” Ashfield executives say.
Combining experts from Ashfield Health, Ashfield Engage and Ashfield Advisory, EmerGENE aims to unlock the potential of cell and gene therapy, helping drug developers to bring transformational treatments to patients.
“At Ashfield, we look to embed ourselves into our customers’ businesses and use our expertise to create tangible solutions which best meet their needs,” says Amar Urhekar, global president at Ashfield Health. “EmerGENE is no different, and with over 1,200 cell and gene therapy clinical trials currently underway globally, and 1,000 different manufacturers exploring cell and gene therapies right now, it’s clear that there is demand for support in this space.
“EmerGENE is the first network approach to offer this unique, end-to-end offering and we’re confident that both new and existing customers will benefit from having access to everything they need from one partner.”